Mevalonate pathway: Difference between revisions
| Line 26: | Line 26: | ||
| [[Acetyl-CoA]] ([[citric acid cycle]]) is converted to [[acetoacetyl-CoA]] || || [[thiolase]] | | [[Acetyl-CoA]] ([[citric acid cycle]]) is converted to [[acetoacetyl-CoA]] || || [[thiolase]] | ||
|- | |- | ||
| Acetyl-CoA condenses with acetoacetyl-CoA to form | | Acetyl-CoA condenses with acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). || [[Image:HMG-CoA synthase.png|center|400px]] || [[HMG-CoA synthase]] | ||
|- | |- | ||
| HMG-CoA is reduced to [[mevalonate]] by [[NADPH]]. This reaction occurs in the cytosol. It is the committed step in cholesterol synthesis, which is why the enzyme catalyzing the reaction is a target of [[statin]]s. || [[Image:Cholesterol-Synthesis-Reaction2.png|center|400px]] || [[HMG-CoA reductase]] | | HMG-CoA is reduced to [[mevalonate]] by [[NADPH]]. This reaction occurs in the cytosol. It is the committed step in cholesterol synthesis, which is why the enzyme catalyzing the reaction is a target of [[statin]]s. || [[Image:Cholesterol-Synthesis-Reaction2.png|center|400px]] || [[HMG-CoA reductase]] | ||
|- | |- | ||
| Mevalonate to | | Mevalonate to 5-phosphomevalonate. || [[Image:Cholesterol-Synthesis-Reaction3.png|center|400px]] || [[mevalonate kinase]] | ||
|- | |- | ||
| 5-phosphomevalonate to [[5-pyrophosphomevalonate]]. || [[Image:Cholesterol-Synthesis-Reaction4.png|center|400px]] || [[phosphomevalonate kinase]] | | 5-phosphomevalonate to [[5-pyrophosphomevalonate]]. || [[Image:Cholesterol-Synthesis-Reaction4.png|center|400px]] || [[phosphomevalonate kinase]] | ||
Revision as of 18:44, 2 July 2009
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
The mevalonate pathway or HMG-CoA reductase pathway or mevalonate-dependent (MAD) route, is an important cellular metabolic pathway present in all higher eukaryotes and many bacteria. It is important for the production of dimethylallyl pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP), which serve as the basis for the biosynthesis of molecules used in processes as diverse as protein prenylation, cell membrane maintenance, hormones, protein anchoring, and N-glycosylation. It is also a part of steroid biosynthesis.
Regulation and feedback
Several key enzymes can be activated through DNA transcriptional regulation on activation of SREBP (Sterol Regulatory Element-Binding Protein-1 and -2). This intracellular sensor detects low cholesterol levels and stimulates endogenous production by the HMG-CoA reductase pathway, as well as increasing lipoprotein uptake by up-regulating the LDL receptor. Regulation of this pathway is also achieved by controlling the rate of translation of the mRNA, degradation of reductase and phosphorylation.
- For more information on regulation, see HMG-CoA reductase
Pharmacology
A number of drugs target the mevalonate pathway:
- Statins (used for elevated cholesterol levels);
- Bisphosphonates (used in treatment of various bone-degenerative diseases)
Alternative
Plants and apicomplexan protozoa such as malaria parasites have the ability to produce their isoprenoids (terpenoids) using an additional alternative pathway called the methylerythritol phosphate (MEP) or non-mevalonate pathway, which takes place in their plastids. In addition, most eubacteria including important pathogens, such as Mycobacterium tuberculosis, synthesize IPP and DMAPP via the non-mevalonate pathway instead.
Reactions
| Reaction | Diagram | Enzyme |
| Acetyl-CoA (citric acid cycle) is converted to acetoacetyl-CoA | thiolase | |
| Acetyl-CoA condenses with acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). |  |
HMG-CoA synthase |
| HMG-CoA is reduced to mevalonate by NADPH. This reaction occurs in the cytosol. It is the committed step in cholesterol synthesis, which is why the enzyme catalyzing the reaction is a target of statins. |  |
HMG-CoA reductase |
| Mevalonate to 5-phosphomevalonate. |  |
mevalonate kinase |
| 5-phosphomevalonate to 5-pyrophosphomevalonate. |  |
phosphomevalonate kinase |
| Mevalonate-5-pyrophosphate to 3-isopentenyl pyrophosphate (IPP) (see also HIDS). |   |
mevalonate-5-pyrophosphate decarboxylase |
| 3-isopentenyl pyrophosphate is isomerized to dimethylallyl pyrophosphate. |  |
isopentenyl pyrophosphate isomerase |
References
- Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th ed. New York: W.H. Freeman. xxxviii, 974, [976] (various pagings). ISBN 0-7167-4684-0.
- Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets 2006;6:15-37. PMID 16475974.
External Links
- Rensselaer Polytechnic Institute page on cholesterol synthesis (including regulation)